BRIEF published on 04/24/2025 at 14:05, 7 months 11 days ago Eckert & Ziegler Signs Manufacturing Agreement with Pentixapharm Clinical Trials Cancer Therapy Manufacturing Agreement Radiopharmaceuticals Y90-PentixaTher
PRESS RELEASE published on 04/24/2025 at 14:00, 7 months 11 days ago Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm Eckert & Ziegler SE signs manufacturing agreement with Pentixapharm for Y90-PentixaTher, a targeted radiolabeled peptide therapeutic for cancer treatment Manufacturing Agreement Eckert & Ziegler SE Radiopharmaceuticals Pentixapharm Y90-PentixaTher
BRIEF published on 04/11/2025 at 10:35, 7 months 24 days ago Eckert & Ziegler Proposes €0.50 Dividend for FY 2024 Annual General Meeting Dividend Eckert & Ziegler Financial Year 2024 TecDax
PRESS RELEASE published on 04/11/2025 at 10:30, 7 months 24 days ago Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024 Eckert & Ziegler SE proposes dividend of €0.50 per share for FY 2024. The Annual General Meeting to be held on June 18, 2025 in Berlin Annual General Meeting Shareholders Dividend Eckert & Ziegler SE FY 2024
BRIEF published on 04/10/2025 at 15:05, 7 months 25 days ago Eckert & Ziegler: US Consul Visits Braunschweig Radiopharmaceutical Facility Cancer Treatment Radiopharmaceuticals Lutetium-177 US Consul Visit Expansion Investment
PRESS RELEASE published on 04/10/2025 at 15:00, 7 months 25 days ago Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig US Consul General Jason Chue visits Eckert & Ziegler's radiopharmaceutical production site in Braunschweig, witnessing the production of cancer diagnostics and therapy solutions Eckert & Ziegler Cancer Therapy Radiopharmaceuticals Lutetium-177 Transatlantic Cooperation
BRIEF published on 03/27/2025 at 07:50, 8 months 9 days ago Eckert & Ziegler Reports Record Year in 2024 Eckert & Ziegler 2024 Financial Results Medical Segment Isotope Products 2025 Forecast
PRESS RELEASE published on 03/27/2025 at 07:45, 8 months 9 days ago Eckert & Ziegler: Record year 2024 with new all-time highs Eckert & Ziegler SE achieved record sales of €295.8 million in 2024, with significant growth in Medical and Isotope Products segments. Forecasting sales of €320 million and EBIT of €78 million for 2025 Record Sales Eckert & Ziegler SE 2024 Financial Year Medical Segment Isotope Products Segment
BRIEF published on 03/25/2025 at 09:35, 8 months 11 days ago Eckert & Ziegler to Provide Actinium Pharmaceuticals with Actinium-225 Clinical Trials Acute Myeloid Leukemia Actinium-225 Supply Targeted Radiotherapy Global Shortage
PRESS RELEASE published on 03/25/2025 at 09:30, 8 months 11 days ago Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities Eckert & Ziegler SE to supply Actinium Pharmaceuticals with Ac-225 for comprehensive development activities, targeting cancer treatment with radiotherapies Cancer Treatment Eckert & Ziegler SE Radiotherapy Ac-225 Actinium Pharmaceuticals
Published on 12/05/2025 at 17:00, 13 minutes ago Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 1 hour 13 minutes ago SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 1 hour 28 minutes ago Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 1 hour 38 minutes ago XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 17:00, 12 minutes ago EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 47 minutes ago 4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 3 minutes ago Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 1 hour 13 minutes ago EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 1 hour 13 minutes ago EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 15:10, 2 hours 2 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 8 hours 28 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 23 hours 13 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 23 hours 28 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 23 hours 29 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
